Table 1 Preoperative patients’ characteristics
Variable | L-PCLND | O-PCLND | p Value |
|---|---|---|---|
N = 46 | N = 21 | ||
histology of orchiectomy; n (%) *2 | |||
seminoma*2 | 12 (26.0) | 6 (28.5) | 1.000 *1 |
pure seminoma | 2 (4.3) | 0 (0) | 1.000 *1 |
teratoma*2 | 9 (19.5) | 4 (19.0) | 1.000 *1 |
embryonal cell carcinoma | 25 (54.3) | 10 (47.6) | 0.558 *1 |
pure embryonal cell carcinoma | 16 (34.7) | 2 (9.5) | 0.030 *1 |
chorioncarcinoma*2 | 2 (4.3) | 4 (19.0) | 0.077 *1 |
yolk sack*2 | 7 (15.2) | 8 (38.0) | 0.055 *1 |
IGCCCG risk score before chemotherapy; n (%) | |||
good | 29 (63.0) | 8 (38.1) | 0.021 *1 |
intermediate | 9 (19.6) | 1 (4.8) | |
poor | 6 (13.0) | 8 (38.1) | 0.072 *1 |
missing | 2 (4.3) | 4 (19.0) | |
Tumor markers before chemotherapy; n (%) | |||
Not elevated | 5 (10.9) | 1 (4.8) | 0.065 *1 |
S1 | 30 (65.2) | 8 (38.1) | |
S2 | 5 (10.9) | 5 (23.8) | |
S3 | 6 (13.0) | 7 (33.3) | |
Tumor markers after chemotherapy; n (%) | |||
Not elevated | 38 (82.6) | 15 (71.4) | 0.545 *1 |
S1 | 6 (13.0) | 4 (19.0) | |
missing | 2 (4.3) | 2 (9.5) | |
Cycles of chemotherapy preop; median (range) | 3 (3-8) | 4 (3-7) | 0.005 *3 |
Salvage chemotherapy; n (%) | 0 (0) | 2 (9.5) | 0.095 *1 |